Nabi Biopharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1967-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.nabi.com
Clinical Trials
18
Active:0
Completed:17
Trial Phases
4 Phases
Phase 1:2
Phase 2:2
Phase 3:12
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
Phase 3
12 (70.6%)Phase 1
2 (11.8%)Phase 2
2 (11.8%)Phase 4
1 (5.9%)A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers
Phase 3
Completed
- Conditions
- Smoking
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 260
- Registration Number
- NCT01375933
- Locations
- 🇺🇸
NicVAX Investigator, Rockville, Maryland, United States
A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation
Completed
- Conditions
- Smoking CessationNicotine Dependence
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT01304810
- Locations
- 🇺🇸
NicVAX Investigator, Seattle, Washington, United States
Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies
Phase 3
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2010-08-10
- Last Posted Date
- 2012-05-09
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT01178346
- Locations
- 🇺🇸
NicVAX Investigator, Madison, Wisconsin, United States
🇺🇸NicVAX, Indianapolis, Indiana, United States
A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation
Phase 3
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2010-04-12
- Last Posted Date
- 2012-05-09
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 1000
- Registration Number
- NCT01102114
- Locations
- 🇺🇸
NicVAX Investigator, Charleston, West Virginia, United States
NicVAX/Placebo as an Aid for Smoking Cessation
Phase 3
Completed
- Conditions
- Smoking CessationSmokingTobacco Cessation
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2012-05-09
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 1000
- Registration Number
- NCT00836199
- Locations
- 🇺🇸
NicVAX Investigator, Madison, Wisconsin, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found